Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30728421 | 0.81 | EPHX1 (0.46) | MEN1KMT2AGAAALDH1A1CA2 | |
| SCHEMBL138368 | 0.81 | LMNA (0.68) | MEN1KMT2AGAACA2PTGS2 | |
| SCHEMBL139599 | 0.80 | PTGS1 (0.51) | MEN1KMT2AGAAALDH1A1CA2 | |
| SCHEMBL139590 | 0.79 | HPGD (0.51) | KMT2ACA2HPGDPTGS2PTGS1 | |
| SCHEMBL140457 | 0.79 | PTGS1 (0.50) | MEN1KMT2AALDH1A1CA2HPGD | |
| SCHEMBL138377 | 0.79 | NPSR1 (0.46) | KMT2AALDH1A1CA2HPGDLMNA | |
| SCHEMBL138372 | 0.79 | KDM4E (0.61) | MEN1KMT2AGAAALDH1A1CA2 | |
| SCHEMBL141242 | 0.78 | PTGS1 (0.58) | MEN1KMT2AALDH1A1CA2HPGD | |
| SCHEMBL20906520 | 0.77 | CA2 (0.64) | MEN1KMT2ACA2HPGDLMNA | |
| SCHEMBL17201441 | 0.77 | CA2 (0.55) | CA2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059179-A1 | PALLADIUM-CATALYZED ORTHO-FLUORINATION | The Scripps Research Insitiute (US) | 2012-03-08 | — | — | US | disclosed |
| WO-2010115098-A2 | PALLADIUM-CATALYZED ORTHO-FLUORINATION | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059179-A1 | PALLADIUM-CATALYZED ORTHO-FLUORINATION | POF1B, OCIAD2, ODC1 | MEN1 424/4885KMT2A 275/4885GAA 3879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.